Acta Pharmaceutica Sinica B · 2021 · 49 citations · 23 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyMitochondrial SignalingMitochondrial ToxicityReactive Oxygen SpeciesTumor Microenvironment ModulationAntitumor Immune ActivationCancer Immunotherapy NanoparticlesIntratumoral AdministrationMitochondrial Oxidative StressMitochondrial Reactive Oxygen Species ProductionMitochondrial Targeting Of NanoparticlesOxidative Stress In CancerPd-l1 Blockade
Immunogenic cell death (ICD) plays a major role in cancer immunotherapy by stimulating specific T cell responses and restoring the antitumor immune system. However, effective type II ICD inducers without biotoxicity are still very limited. Herein, a tentative drug- or photosensitizer-free strategy was developed by employing enzymatic self-assembly of the peptide F-pY-T to induce mitochondrial oxidative stress in cancer cells. Upon dephosphorylation catalyzed by alkaline phosphatase overexpressed on cancer cells, the peptide F-pY-T self-assembled to form nanoparticles, which were subsequently internalized. These affected the morphology of mitochondria and induced serious reactive oxygen species production, causing the ICD characterized by the release of danger-associated molecular patterns (DAMPs). DAMPs enhanced specific immune responses by promoting the maturation of DCs and the intratumoral infiltration of tumor-specific T cells to eradicate tumor cells. The dramatic immunotherapeutic capacity could be enhanced further by combination therapy of F-pY-T and anti-PD-L1 agents without visible biotoxicity in the main organs. Thus, our results revealed an alternative strategy to induce efficient ICD by physically promoting mitochondrial oxidative stress.
23
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Reactive Oxygen Species (Ros-Induced) Ros Release
Dmitry B. Zorov, Charles R. Filburn, Lars‐Oliver Klotz et al. · The Journal of Experimental Medicine · 2000 · 1.4K citations · Full text
Immunogenic death of colon cancer cells treated with oxaliplatin
Antoine Tesnière, F. Schlemmer, Valérie Boige et al. · Oncogene · 2009 · 1.1K citations
Medicine, Oncology, Pharmacology +14